What does the SURMOUNT trial data actually show?
The SURMOUNT-1 trial is the primary source for tirzepatide weight loss data in adults with obesity who did not have type 2 diabetes. The trial enrolled 2,539 participants and ran for 72 weeks, tracking weight loss at three maintenance doses: 5 mg, 10 mg, and 15 mg weekly.
The mean weight reductions from the 72-week trial were:
- 5 mg tirzepatide weekly: mean weight loss of approximately 15.0% of body weight (roughly 34 lbs / 15.4 kg from a mean starting weight near 231 lbs)
- 10 mg tirzepatide weekly: mean weight loss of approximately 19.5% of body weight
- 15 mg tirzepatide weekly: mean weight loss of approximately 20.9% of body weight
- Placebo: mean weight loss of approximately 3.1% of body weight
The higher-dose groups (10 mg and 15 mg) showed the most pronounced effect, with the 15 mg group achieving a mean that exceeded 20% body weight reduction — a benchmark that had previously only been achievable through bariatric surgery in most patients.
| Weekly dose | Mean % body weight lost (72 wk) | Approx. lbs lost (from ~231 lb baseline) | % achieving ≥20% loss |
|---|---|---|---|
| 5 mg | ~15.0% | ~35 lbs | ~15% |
| 10 mg | ~19.5% | ~45 lbs | ~36% |
| 15 mg | ~20.9% | ~48 lbs | ~57% |
| Placebo | ~3.1% | ~7 lbs | <1% |
Source: SURMOUNT-1 trial (Jastreboff et al., NEJM 2022). All figures are trial means for patients without type 2 diabetes; individual results vary.
What does the weight loss curve look like over time?
Understanding when average weight loss on tirzepatide accumulates matters as much as knowing the total endpoint figure. The SURMOUNT-1 data shows a characteristic curve:
Weeks 1–8: Dose escalation phase
Patients begin at 2.5 mg weekly and step up by 2.5 mg every four weeks. During this phase, appetite suppression begins but weight loss is relatively modest — often 3 to 7 lbs depending on individual adherence and dietary changes. The body is adapting to the medication; GI side effects are most common during dose transitions.
Weeks 8–28: Steepest weight loss period
As patients reach and stabilize at maintenance doses, the weight-loss rate accelerates. This is typically the period patients describe as the most active phase — appetite suppression is consistent, portion sizes shrink without effort, and the scale moves reliably week to week. Clinical trial weight-loss curves show their steepest slopes during this window.
Weeks 28–72: Plateau and stabilization
Weight loss continues in the second half of the trial but at a slower rate. Most patients reach a plateau — the point at which reduced caloric intake matches reduced metabolic rate. The 72-week endpoint figures represent the cumulative loss through this full arc, not the rate at any single moment.
Why can the average mislead individual expectations?
The SURMOUNT-1 mean figures are genuine and meaningful — they come from a large, well-designed trial. But the distribution around those means is wide. Understanding what drives variation helps patients calibrate realistic expectations.
High responders
In the 15 mg group, a substantial proportion of participants lost more than 25% of their body weight. Some individuals lost over 30%. These high-response outcomes generated much of the initial excitement around tirzepatide and are accurately represented in the SURMOUNT data — they represent real patients, not statistical outliers that were excluded.
Non-responders
Roughly 10 to 15% of tirzepatide trial participants lost less than 5% of body weight over 72 weeks — a level of response considered clinically insufficient for weight management. The biological reasons for non-response are not fully understood and likely involve a combination of genetic variation in GIP and GLP-1 receptor expression, gut microbiome differences, and compensatory metabolic adaptations.
Factors that influence individual response
- Insulin sensitivity at baseline: Patients with greater insulin resistance often show stronger early responses to dual GIP/GLP-1 agonism.
- Dietary quality: Tirzepatide reduces appetite but does not independently change food quality. Patients who make meaningful dietary changes alongside the medication typically see better outcomes.
- Physical activity: Exercise independently contributes to the metabolic environment and appears to help preserve lean mass during weight loss, improving body composition outcomes even when total weight loss is similar.
- Adherence and GI tolerance: Patients who are unable to tolerate dose escalation or who require extended time at lower doses achieve less weight loss on average because they spend more of the treatment period below therapeutic dose.
- Starting weight: Because results are typically expressed as percentage of body weight, heavier patients lose more in absolute pounds while percentage loss tends to converge.
At the 15 mg dose, SURMOUNT-1 patients lost a mean of 20.9%of body weight over 72 weeks — but roughly one in eight lost less than 5%.
Tirzepatide vs. semaglutide: what does the head-to-head data show?
For patients who have researched both GLP-1 receptor agonists, the relevant comparison is the SURMOUNT-5 trial, a direct head-to-head comparison of tirzepatide (10 and 15 mg) versus semaglutide (2.4 mg). Published in 2025, SURMOUNT-5 showed that tirzepatide produced approximately 47% greater weight loss than semaglutide over 72 weeks in its primary analysis — approximately 20% vs 14% mean body weight reduction.
This data represents the first large-scale head-to-head comparison and establishes tirzepatide as the more potent option for average weight reduction when comparing at approved doses. However, semaglutide may be preferred for individual patients based on tolerability, access, cost, or clinical considerations — a decision that belongs in a clinician conversation, not a website article.
What happens to weight loss when tirzepatide is stopped?
An important dimension of average weight loss on tirzepatide that is often underemphasized in popular coverage: the weight loss is maintained primarily for as long as the medication is continued. The SURMOUNT-4 trial (the withdrawal study) showed that participants who discontinued tirzepatide after 36 weeks regained approximately two-thirds of the lost weight over the following year.
This is not unique to tirzepatide — it is characteristic of the entire class of GLP-1 receptor agonists and reflects that these medications address a physiological driver of weight management (appetite signaling) rather than permanently altering body weight set points. Patients considering tirzepatide should understand that maintaining results typically requires ongoing use, and this should factor into both clinical planning and cost expectations.
How do you access compounded tirzepatide?
Compounded tirzepatide is available through licensed 503A pharmacies in the United States when prescribed by a licensed clinician. It is not an FDA-approved medication. Compounded medications are prepared to individual patient prescriptions; they are not bioequivalence-tested against the branded product.
PepScribe connects patients with licensed clinicians who evaluate individual health history and weight management goals before recommending a protocol. Medications are compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain.
Learn more about how PepScribe’s clinician-supervised tirzepatide program works.
Frequently asked questions
What is the average weight loss on tirzepatide?
In the SURMOUNT-1 trial, adults with obesity taking tirzepatide at 15 mg weekly lost an average of approximately 20.9% of body weight over 72 weeks. At 10 mg, the average was approximately 19.5%. At 5 mg, the average was approximately 15%. These are trial averages across a selected population — individual results vary considerably.
How much weight can you lose on tirzepatide in 3 months?
At 3 months (approximately week 12), most patients are still in the dose-escalation phase and have not reached their maintenance dose. Average weight loss at this stage is typically in the range of 5–10% of body weight, though this varies considerably by individual. The most pronounced loss occurs between weeks 8 and 36.
Is tirzepatide or semaglutide better for weight loss?
Head-to-head trial data (SURMOUNT-5) showed tirzepatide produced greater average weight loss than semaglutide at their respective highest approved doses — approximately 20% vs 14% over 72 weeks. However, individual response varies, and the right choice depends on patient-specific factors a clinician should evaluate.
How long does it take to see results on tirzepatide?
Most patients notice appetite suppression within the first 1–2 weeks. Measurable weight change becomes more pronounced between weeks 8 and 28 as the dose escalates toward the maintenance range. The full weight-loss effect of the medication typically develops over 6–18 months.
Does tirzepatide work for everyone?
No weight management medication works equally for everyone. In the SURMOUNT trials, a proportion of participants (roughly 10–15%) were considered non-responders who lost less than 5% of body weight. Factors including genetics, starting insulin sensitivity, dietary patterns, and adherence all influence response.
Can you get compounded tirzepatide?
Compounded tirzepatide is available through licensed 503A compounding pharmacies in the US when prescribed by a licensed clinician. It is not an FDA-approved product. PepScribe connects patients with licensed clinicians who assess whether compounded tirzepatide is appropriate for an individual patient.